In the US pharmaceutical industry, there were 245 M&A deals announced in Q2 2023, worth a total value of $35.9bn, according to GlobalData’s Deals Database. The $10.8bn acquisition of prometheus biosciences by merck was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, M&A activity in The US decreased by 44% in Q2 2023 compared with the previous quarter’s total of $64.5bn and rose by 53% as compared to Q2 2022. Related deal volume increased by 24% in Q2 2023 versus the previous quarter and was 172% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in The US in Q2 2023 were Centerview Partners; Stifel Financial; Goldman Sachs Group with 11, 6, 5 deals respectively.
The top-ranked legal advisorss supporting these M&A deals in The US Q2 2023 were Kirkland & Ellis; Cooley; Gibson, Dunn & Crutcher with 13, 12, 11 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.